Management of immunocompromised patients with evidence of an invasive mycosis

Area of Science:

• Medical Mycology
• Infectious Diseases
• Hematology-Oncology

Background:

• Invasive fungal infections (IFIs) significantly contribute to morbidity and mortality in immunocompromised individuals, especially those with granulocytopenia and human immunodeficiency virus (HIV) infection.
• Commonly implicated fungi include Candida spp. and Aspergillus spp., but emerging pathogens present evolving diagnostic and therapeutic challenges.
• Effective management hinges on accurate identification of the causative fungal species and the affected anatomical sites.

Purpose of the Study:

• To summarize the current diagnostic and therapeutic approaches for invasive fungal infections.
• To describe the management protocols implemented at the National Cancer Institute's Pediatric Branch.
• To address the challenges posed by both common and emerging fungal pathogens in pediatric oncology.

Main Methods:

• Review of existing literature on invasive fungal infections.
• Analysis of treatment protocols and clinical guidelines.
• Case study review from the National Cancer Institute's Pediatric Branch (specific details not provided in abstract).

Main Results:

• Candida spp. and Aspergillus spp. are identified as primary fungal pathogens in granulocytopenic patients.
• Emerging fungal pathogens are increasingly recognized as significant threats.
• Management strategies are tailored based on fungal type and infection site.

Conclusions:

• Invasive fungal infections require prompt and accurate diagnosis for effective treatment.
• A multidisciplinary approach is crucial for managing IFIs in immunocompromised pediatric patients.
• Continuous adaptation of treatment strategies is necessary to combat evolving fungal resistance and emerging pathogens.